Chunghwa Chemical Synthesis & Biotech Co., Ltd.
Taiwan Stock ExchangeTotal Valuation
Chunghwa Chemical Synthesis & Biotech Co., Ltd. carries a market capitalization of 3.03B, placing it among publicly traded companies globally. Its enterprise value stands at 1.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.03B |
| Enterprise Value | 1.95B |
Share Statistics
Chunghwa Chemical Synthesis & Biotech Co., Ltd. currently has 76.92M shares outstanding.
| Shares Outstanding | 76.92M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Chunghwa Chemical Synthesis & Biotech Co., Ltd. trades at a trailing price-to-earnings ratio of 80.22. The price-to-sales ratio is 1.69, and the price-to-book ratio stands at 0.62.
| PE Ratio | 80.22 |
| PS Ratio | 1.69 |
| PB Ratio | 0.62 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | 6.65 |
| P/OCF Ratio | 9.56 |
Enterprise Valuation
| EV / Sales | 2.43 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 8.84 |
Financial Position
Chunghwa Chemical Synthesis & Biotech Co., Ltd. maintains a current ratio of 2.97, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.10, indicating elevated leverage, while an interest coverage ratio of -19.10 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.97 |
| Quick Ratio | 0.61 |
| Debt / Equity | 26.10 |
| Debt / EBITDA | -2.52 |
| Interest Coverage | -19.10 |
Financial Efficiency
| Return on Equity (ROE) | -10.34 |
| Return on Assets (ROA) | -5.37 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.96 |
Taxes
| Income Tax | -11.83M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s stock has gained approximately 50.57252% over the past 52 weeks. The 50-day moving average sits at 36.53, while the 200-day moving average is 28.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | 50.57252% |
| 50-Day Moving Average | 36.53 |
| 200-Day Moving Average | 28.89 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Chunghwa Chemical Synthesis & Biotech Co., Ltd. generated 804.88M in revenue and converted that into -243.85M in net income, yielding earnings per share of -4.38. EBITDA reached -319.54M, while operating income came in at -319.54M.
| Revenue | 804.88M |
| Gross Profit | -8.86M |
| Operating Income | -319.54M |
| Pretax Income | -255.68M |
| Net Income | -243.85M |
| EBITDA | -319.54M |
| EBIT | -319.54M |
| Earnings Per Share (EPS) | -4.38 |
Balance Sheet
Chunghwa Chemical Synthesis & Biotech Co., Ltd. holds 216.44M in cash and equivalents against 805.86M in total debt, resulting in a net debt position of 584.85M. Total book value stands at 2.22B, with working capital of 702.18M providing operational flexibility.
| Cash & Cash Equivalents | 216.44M |
| Total Debt | 805.86M |
| Net Debt | 584.85M |
| Equity (Book Value) | 2.22B |
| Book Value Per Share | 39.82 |
| Working Capital | 702.18M |
Cash Flow
Chunghwa Chemical Synthesis & Biotech Co., Ltd. produced 142.61M in operating cash flow over the past twelve months. After subtracting -62.33M in capital expenditures, free cash flow totaled 80.28M - equivalent to 1.44 per share.
| Operating Cash Flow | 142.61M |
| Capital Expenditures | -62.33M |
| Free Cash Flow | 80.28M |
| FCF Per Share | 1.44 |
Margins
Chunghwa Chemical Synthesis & Biotech Co., Ltd. operates with a gross margin of -1.10, reflecting its pricing power and cost economics. The operating margin of -39.70 and net profit margin of -30.30 provide insight into operational efficiency.
| Gross Margin | -1.10 |
| Operating Margin | -39.70 |
| Pretax Margin | -31.77 |
| Profit Margin | -30.30 |
| EBITDA Margin | -39.70 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 6.31 |
| FCF Yield | 15.03 |
Scores
Chunghwa Chemical Synthesis & Biotech Co., Ltd. posts an Altman Z-Score of 1.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.27 |